JP2018509457A - ブルトン型チロシンキナーゼ阻害剤の溶媒和形態 - Google Patents

ブルトン型チロシンキナーゼ阻害剤の溶媒和形態 Download PDF

Info

Publication number
JP2018509457A
JP2018509457A JP2017550541A JP2017550541A JP2018509457A JP 2018509457 A JP2018509457 A JP 2018509457A JP 2017550541 A JP2017550541 A JP 2017550541A JP 2017550541 A JP2017550541 A JP 2017550541A JP 2018509457 A JP2018509457 A JP 2018509457A
Authority
JP
Japan
Prior art keywords
theta
crystalline form
solvate
same
xrpd
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017550541A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018509457A5 (enExample
Inventor
ゴールドマン，エリック
スミス，マーク，スティーブン
ボノード，ティエリー
ガルシア，アルバート ムニョス
ガルシア，アルバート ムニョス
ウォラル，クリストファー，ピーター
Original Assignee
ファーマサイクリックス エルエルシー
ファーマサイクリックス エルエルシー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ファーマサイクリックス エルエルシー, ファーマサイクリックス エルエルシー filed Critical ファーマサイクリックス エルエルシー
Publication of JP2018509457A publication Critical patent/JP2018509457A/ja
Publication of JP2018509457A5 publication Critical patent/JP2018509457A5/ja
Priority to JP2021187233A priority Critical patent/JP2022033783A/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N23/00—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00
    • G01N23/20—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00 by using diffraction of the radiation by the materials, e.g. for investigating crystal structure; by using scattering of the radiation by the materials, e.g. for investigating non-crystalline materials; by using reflection of the radiation by the materials
    • G01N23/20075—Investigating or analysing materials by the use of wave or particle radiation, e.g. X-rays or neutrons, not covered by groups G01N3/00 – G01N17/00, G01N21/00 or G01N22/00 by using diffraction of the radiation by the materials, e.g. for investigating crystal structure; by using scattering of the radiation by the materials, e.g. for investigating non-crystalline materials; by using reflection of the radiation by the materials by measuring interferences of X-rays, e.g. Borrmann effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
JP2017550541A 2015-03-27 2016-03-25 ブルトン型チロシンキナーゼ阻害剤の溶媒和形態 Pending JP2018509457A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2021187233A JP2022033783A (ja) 2015-03-27 2021-11-17 ブルトン型チロシンキナーゼ阻害剤の溶媒和形態

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562139594P 2015-03-27 2015-03-27
US62/139,594 2015-03-27
PCT/US2016/024305 WO2016160598A1 (en) 2015-03-27 2016-03-25 Solvated forms of a bruton's tyrosine kinase inhibitor

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021187233A Division JP2022033783A (ja) 2015-03-27 2021-11-17 ブルトン型チロシンキナーゼ阻害剤の溶媒和形態

Publications (2)

Publication Number Publication Date
JP2018509457A true JP2018509457A (ja) 2018-04-05
JP2018509457A5 JP2018509457A5 (enExample) 2019-05-09

Family

ID=57006292

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2017550541A Pending JP2018509457A (ja) 2015-03-27 2016-03-25 ブルトン型チロシンキナーゼ阻害剤の溶媒和形態
JP2021187233A Pending JP2022033783A (ja) 2015-03-27 2021-11-17 ブルトン型チロシンキナーゼ阻害剤の溶媒和形態

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2021187233A Pending JP2022033783A (ja) 2015-03-27 2021-11-17 ブルトン型チロシンキナーゼ阻害剤の溶媒和形態

Country Status (11)

Country Link
US (4) US20180072738A1 (enExample)
EP (1) EP3273961A4 (enExample)
JP (2) JP2018509457A (enExample)
CN (1) CN107530346A (enExample)
AU (1) AU2016243116A1 (enExample)
BR (1) BR112017020744A2 (enExample)
CA (1) CA2981048A1 (enExample)
HK (2) HK1249737A1 (enExample)
MA (1) MA41827A (enExample)
MX (1) MX2017012430A (enExample)
WO (1) WO2016160598A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA201492082A1 (ru) 2012-06-04 2015-03-31 Фармасайкликс, Инк. Кристаллические формы ингибитора тирозинкиназы брутона
IL315294A (en) 2015-03-03 2024-10-01 Pharmacyclics Llc Pharmaceutical formulations of bruton's tyrosine kinase inhibitor
US11001585B2 (en) 2015-08-19 2021-05-11 Sun Pharmaceutical Industries Limited Crystalline forms of ibrutinib
CZ2016276A3 (cs) * 2016-05-11 2017-11-22 Zentiva, K.S. Pevné formy volné báze ibrutinibu
US10183024B2 (en) 2016-12-02 2019-01-22 Apotex Inc. Crystalline forms of ibrutinib
CZ2017787A3 (cs) 2017-12-08 2019-06-19 Zentiva, K.S. Farmaceutické kompozice obsahující ibrutinib
EP3575300A1 (en) 2018-05-31 2019-12-04 Apotex Inc. Novel crystalline forms of ibrutinib
US10688050B1 (en) 2018-12-21 2020-06-23 Synthon B.V. Pharmaceutical composition comprising ibrutinib
EP3669867A1 (en) 2018-12-21 2020-06-24 Synthon B.V. Pharmaceutical composition comprising ibrutinib
MX2022003340A (es) * 2019-09-18 2022-06-14 Prelude Therapeutics Inc Inhibidores selectivos de la proteina arginina metiltransferasa 5 (prmt5).
CN114478547A (zh) * 2020-10-23 2022-05-13 上海润石医药科技有限公司 固体形式的布鲁顿酪氨酸激酶抑制剂化合物及其用途
WO2023242384A1 (en) 2022-06-17 2023-12-21 Krka, D.D., Novo Mesto Crystalline form of ibrutinib

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05239476A (ja) * 1983-02-04 1993-09-17 Huels Troisdorf Ag オルガノシロキサン燃料添加剤
JP2002544208A (ja) * 1999-05-12 2002-12-24 シンジェンタ パーティシペーションズ アクチェンゲゼルシャフト ピメトロジンの溶媒和物
JP2004521082A (ja) * 2000-10-05 2004-07-15 アベンティス・ファーマスーティカルズ・インコーポレイテツド 新規な結晶形のＸａ因子阻害剤
JP2010526768A (ja) * 2007-03-28 2010-08-05 ファーマサイクリックス，インク． ブルトンチロシンキナーゼインヒビター
US20120238733A1 (en) * 2011-03-14 2012-09-20 Los Alamos National Security, Llc Preparation of cerium halide solvate complexes
US20120277177A1 (en) * 2010-10-28 2012-11-01 Amparo Eugene C Crystalline phases of 5,6-dichloro-2-(isopropylamino)-1-beta-ribofuranosyl-1h-benzimidazole
WO2013184572A1 (en) * 2012-06-04 2013-12-12 Pharmacyclics, Inc. Crystalline forms of a bruton's tyrosine kinase inhibitor
CN103923084A (zh) * 2014-01-29 2014-07-16 苏州晶云药物科技有限公司 几种新晶型及其制备方法
WO2014168975A1 (en) * 2013-04-08 2014-10-16 Pharmacyclics, Inc. Ibrutinib combination therapy

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4327725A (en) 1980-11-25 1982-05-04 Alza Corporation Osmotic device with hydrogel driving member
US4624848A (en) 1984-05-10 1986-11-25 Ciba-Geigy Corporation Active agent containing hydrogel devices wherein the active agent concentration profile contains a sigmoidal concentration gradient for improved constant release, their manufacture and use
US4968509A (en) 1987-07-27 1990-11-06 Mcneilab, Inc. Oral sustained release acetaminophen formulation and process
IL92966A (en) 1989-01-12 1995-07-31 Pfizer Dispensing devices powered by hydrogel
JP2527107B2 (ja) 1991-04-16 1996-08-21 日本新薬株式会社 固体分散体の製造方法
CZ282760B6 (cs) 1991-11-22 1997-09-17 Procter And Gamble Pharmaceuticals, Inc. Risedronátové prostředky se zpožděným uvolňováním
US5461140A (en) 1992-04-30 1995-10-24 Pharmaceutical Delivery Systems Bioerodible polymers for solid controlled release pharmaceutical compositions
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
EP0665010B1 (en) 1992-10-16 2002-09-11 Nippon Shinyaku Company, Limited Method of manufacturing wax matrices
US5686105A (en) 1993-10-19 1997-11-11 The Procter & Gamble Company Pharmaceutical dosage form with multiple enteric polymer coatings for colonic delivery
US6326469B1 (en) 1994-04-22 2001-12-04 Sugen, Inc. Megakaryocytic protein tyrosine kinases
JPH11505258A (ja) 1995-05-17 1999-05-18 セダーシナイ メディカル センター 小腸における消化および吸収を改善させる脂肪酸を含む組成物
US6395300B1 (en) 1999-05-27 2002-05-28 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
US6465014B1 (en) 2001-03-21 2002-10-15 Isp Investments Inc. pH-dependent sustained release, drug-delivery composition
US7711492B2 (en) 2003-09-03 2010-05-04 The United States Of America As Represented By The Department Of Health And Human Services Methods for diagnosing lymphoma types
EP2526934B1 (en) 2006-09-22 2015-12-09 Pharmacyclics LLC Inhibitors of bruton's tyrosine kinase

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH05239476A (ja) * 1983-02-04 1993-09-17 Huels Troisdorf Ag オルガノシロキサン燃料添加剤
JP2002544208A (ja) * 1999-05-12 2002-12-24 シンジェンタ パーティシペーションズ アクチェンゲゼルシャフト ピメトロジンの溶媒和物
JP2004521082A (ja) * 2000-10-05 2004-07-15 アベンティス・ファーマスーティカルズ・インコーポレイテツド 新規な結晶形のＸａ因子阻害剤
JP2010526768A (ja) * 2007-03-28 2010-08-05 ファーマサイクリックス，インク． ブルトンチロシンキナーゼインヒビター
US20120277177A1 (en) * 2010-10-28 2012-11-01 Amparo Eugene C Crystalline phases of 5,6-dichloro-2-(isopropylamino)-1-beta-ribofuranosyl-1h-benzimidazole
US20120238733A1 (en) * 2011-03-14 2012-09-20 Los Alamos National Security, Llc Preparation of cerium halide solvate complexes
WO2013184572A1 (en) * 2012-06-04 2013-12-12 Pharmacyclics, Inc. Crystalline forms of a bruton's tyrosine kinase inhibitor
WO2014168975A1 (en) * 2013-04-08 2014-10-16 Pharmacyclics, Inc. Ibrutinib combination therapy
CN103923084A (zh) * 2014-01-29 2014-07-16 苏州晶云药物科技有限公司 几种新晶型及其制备方法

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
杉本功、高橋嘉輝: "溶媒和物、非晶質固体と医薬品製剤", 紛体工学会誌, vol. 22, no. 2, JPN6017004373, 1985, pages 85 - 97, ISSN: 0004349334 *
芦澤一英, 医薬品の多形現象と晶析の科学, JPN6015027444, 20 September 2002 (2002-09-20), pages 273 - 278, ISSN: 0004349335 *

Also Published As

Publication number Publication date
US20190367519A1 (en) 2019-12-05
AU2016243116A1 (en) 2017-10-19
JP2022033783A (ja) 2022-03-02
EP3273961A4 (en) 2018-10-31
HK1248147A1 (zh) 2018-10-12
HK1249737A1 (zh) 2018-11-09
WO2016160598A1 (en) 2016-10-06
US20180072738A1 (en) 2018-03-15
CA2981048A1 (en) 2016-10-06
US20200347063A1 (en) 2020-11-05
BR112017020744A2 (pt) 2018-07-17
CN107530346A (zh) 2018-01-02
MX2017012430A (es) 2018-07-06
MA41827A (fr) 2018-01-30
US20220106317A1 (en) 2022-04-07
EP3273961A1 (en) 2018-01-31

Similar Documents

Publication Publication Date Title
US20250228783A1 (en) Pharmaceutical formulations of a bruton's tyrosine kinase inhibitor
JP2025176017A (ja) ブルトン型チロシンキナーゼ阻害剤の結晶形態
US20220242868A1 (en) Co-crystals of a bruton's tyrosine kinase inhibitor
US20220106317A1 (en) Solvated forms of a bruton's tyrosine kinase inhibitor
JP2017523206A (ja) ブルトン型チロシンキナーゼ阻害剤の新規製剤
JP2025186225A (ja) ブルトン型チロシンキナーゼ阻害剤の結晶形態
HK40107203A (en) Pharmaceutical formulations of a bruton's tyrosine kinase inhibtor
HK1249015B (en) Pharmaceutical formulations of bruton's tyrosine kinase inhibtor

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190322

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190322

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20191219

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200109

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200331

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200604

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200702

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200923

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201218

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210219

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210323

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20210719

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211117

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20211117

RD13 Notification of appointment of power of sub attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7433

Effective date: 20211201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211202

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20211202

C609 Written withdrawal of request for trial/appeal

Free format text: JAPANESE INTERMEDIATE CODE: C609

Effective date: 20211224

C27A Decision to dismiss

Free format text: JAPANESE INTERMEDIATE CODE: C2711

Effective date: 20220117

C092 Termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C092

Effective date: 20220119

RD14 Notification of resignation of power of sub attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7434

Effective date: 20220627

C092 Termination of reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C092

Effective date: 20220713